Ertugliflozin Tablets 15 mg are an oral sodium–glucose cotransporter 2 (SGLT2) inhibitor.
It works by inhibiting glucose reabsorption in the kidney, increasing urinary glucose excretion, and lowering elevated blood glucose levels in an insulin‑independent manner.
Composition
Each film‑coated tablet contains:
Ertugliflozin …… 15 mg
Indications
For the treatment of type 2 diabetes mellitus in adults:
As monotherapy when diet and exercise alone do not provide adequate glycemic control.
In combination with other antidiabetic medicinal products, including insulin.
Key Features
Selective SGLT2 inhibition with insulin‑independent mechanism
Once‑daily oral administration
Low risk of hypoglycemia when used alone
Associated with mild weight reduction and blood pressure lowering
Good safety and tolerability profile
Manufactured under GMP conditions
Complies with international pharmacopoeial standards
Full registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Contraindicated in patients with hypersensitivity to ertugliflozin or any excipient.
Use with caution in patients with renal impairment, hypotension, or risk of ketoacidosis.
For prescription use only under medical supervision.
